Overview of chlamydia trachomatis infections

RnRMarketResearch.com adds "Chlamydia Trachomatis Infections - Pipeline Review, H1 2015" research to its store. This report provides an overview of the Chlamydia Trachomatis Infections' therapeutic pipeline and key players involved in the therapeutic development for Chlamydia Trachomatis Infections and special features on late-stage and discontinued projects.

The report "Chlamydia Trachomatis Infections - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Chlamydia Trachomatis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chlamydia Trachomatis Infections and special features on late-stage and discontinued projects. Read more at http://www.rnrmarketresearch.com/chlamydia-trachomatis-infections-pipeline-review-h1-2015-market-report.html .

Chlamydia trachomatis infection generally affects the urogenital tract. Chlamydia are small gram-negative necessitate intracellular bacteria that infect squamocolumnar epithelial cells. Chlamydia pneumoniae may spread through coughing and sneezing. In many cases, chlamydia causes no symptoms at all. It is most common in women aged fewer than 25. Adults may also experience conjunctivitis caused by chlamydia.

The report on Chlamydia Trachomatis Infections pipeline review enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269536 . (This is a premium report priced at US$2000 for a single user License.)

Companies discussed in this Chlamydia Trachomatis Infections - Pipeline Review, H2 2014 report include ActivBiotics Pharma, LLC, Big DNA Ltd., Foamix Pharmaceuticals Ltd., Prokarium Ltd.

Drug Profiles discussed in this report include BDNA-003, chlamydia trachomatis vaccine, chlamydia vaccine, minocycline Gel, rifalazil.

Scope of Chlamydia Trachomatis Infections - Pipeline Review, H2 2014 covers: a snapshot of the global therapeutic landscape of Chlamydia Trachomatis Infections; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Chlamydia Trachomatis Infections and enlists all their major and minor projects; report summarizes all the dormant and discontinued pipeline projects; A review of the Chlamydia Trachomatis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Chlamydia Trachomatis Infections pipeline on the basis of target, MoA, route of administration and molecule type as well as Latest news and deals relating related to pipeline products.

Explore more reports on Infectious Diseases Therapeutics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .

Nasopharyngitis (Common Cold) - Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Nasopharyngitis (Common Cold). Nasopharyngitis is a contagious, viral infectious disease of the upper respiratory system, primarily.It is the most common infectious disease in humans. Companies discuss in the report include Cocrystal Pharma, Inc., Neos Therapeutics, Inc., Orbis Biosciences, Inc., Vernalis plc.

Community Acquired Pneumonia - Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Community Acquired Pneumonia. Companies discuss in the report include Actavis plc, AstraZeneca PLC, Biotest AG, C10 Pharma AS, Kyorin Pharmaceutical Co., Ltd., Paratek Pharmaceuticals, Inc., TaiGen Biotechnology Co., Ltd., Takeda Pharmaceutical Company Limited.

Drug Profiles discussed in this report BT-086, C-10, ceftaroline fosamil, dalbavancin, KRPAM-1977X, nemonoxacin, omadacycline, Small Molecules for SSTI and CAP Infections, ticagrelor.

Candidiasis - Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. Companies discuss in the report include Actavis plc, Aureogen Biosciences, Inc., Basilea Pharmaceutica AG, Biomar Microbial Technologies, Cellceutix Corporation, Eisai Co., Ltd., General Biologicals Corporation, Grupo Ferrer Internacional, S.A., iCo Therapeutics Inc., Novabiotics Ltd, NovaDigm Therapeutics, Inc., Novartis AG, Onxeo SA, Panacela Labs, Inc., Scynexis, Inc., Sealife PHARMA GMBH, Sequella, Inc., Viamet Pharmaceuticals, Inc., Wellstat Vaccines, LLC.

Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium). Onychomycosis is a fungal infection of the toenails or fingernails. Onychomycosis causes fingernails or toenails to thicken, discolor, disfigure, and split. Companies discuss in the report include Actavis plc, Anacor Pharmaceuticals, Inc., Eisai Co., Ltd., Evolva SA, Helix BioMedix, Inc., Mayne Pharma Group Limited, Meiji Seika Pharma Co., Ltd., Moberg Pharma AB, NAL Pharmaceuticals Ltd., Nihon Nohyaku Co., Ltd., Novabiotics Ltd, Nuvo Research Inc., Viamet Pharmaceuticals, Inc.

​SOURCE RnR Market Research